Poolbeg Pharma PLC (AIM:POLB) (LON:POLB) CEO Jeremy Skillington answers shareholder questions following his presentation at the Proactive One2one virtual investment forum.
Katie Pilbeam asks the queries from viewers include how Poolbeg’s business model is different and how the original Hvivo staff are involved in the original development of the Immune Modulator.
He talks through some of the upcoming key events, the main site of action for POLB 001 and whether it could potentially be used for other treatments.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. Poolbeg aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.